Due to the heterogenous expression of MSLN in ovarian cancer, we hypothesized that MSLN-targeting CAR (MCAR)-engineered Vδ2 T cells may exhibit superior antitumor activity due to the potential of multiple targeting capability. This evidence concerns the gene MSLN and ovarian cancer.